Underwriting Fixed, Growth Moderating, Regulation Rising

The reported PAT of ₹264.8 Cr leaps 382% year-on-year, but that gap is almost entirely a base-year artifact. In Q2 FY26, the company was still loss-making at ₹80 Cr. When adjusted for the structural shift from loss to profit—rather than the percentage pop—the normalized PAT is ₹390 Cr, up 70% year-over-year. That's the organic number to anchor on. Where it came from: underwriting profit swung ₹139 Cr, from a loss of ₹40 Cr last year to a profit of ₹99 Cr this quarter. The turnaround is real. But the reported 382% masks a softer story: healthy execution on a tougher base, not the blowout the headline suggests.

Star guided for 15–16% insurance revenue growth in the prior call. It delivered 19% gross written premium growth (₹5,275 Cr), with fresh retail health surging 35% year-over-year. The new-to-insurance cohort now sits at 93% of the retail mix, up from 89% a year ago. This is entirely intentional: the company is pivoting to first-time buyers in semi-urban and rural India, trading renewal stability for volume and market-share capture. The underwriting improvement is the centerpiece. For five consecutive quarters, loss ratios have compressed. In H1, the combined insurance service ratio (CISR) improved 2.4 percentage points to 97.9%, with underwriting profit swinging from a loss of ₹24 Cr to a gain of ₹210 Cr. This is not a one-quarter blip. The loss ratio improvement is structural—a mix of better claims management (renewal book showing improvement, fresh business at a ~20% loss ratio slice for now), active hospital negotiations on surgical inflation, and pricing discipline. Normalized return on equity for H1 stands at 15.1% versus 11.2% a year ago. That puts the company squarely in the mid-teen range it has guided for on a steady-state basis. The reinsurance cost target (a decline from 0.9% to 0.5–0.6%) is on track, embedded in the CISR improvement.

Underwriting swing: The loss-to-profit reversal (₹99 Cr this quarter) is the structural change; this is not a reversal we expect to flip back. Five consecutive quarters of improvement give credibility. Revenue beat: 19% growth versus a 15–16% prior guide signals execution and a tighter market-share grab in fresh. But the company is guiding for growth moderation ahead: management expects GST normalization (the exemption expires in October 2026) to create 'optical moderation' in growth rates, even as policy volumes and agent activations continue. Regulatory headwinds introduced: This call flagged three emerging pressures that were not central to the prior dialogue: (1) End-of-month (EoM) caps at 20% on commission spend (current OpEx is ~25–27%, so repricing or cost cuts required); (2) distribution reform (agent exclusivity, multi-company sell constraints); (3) dark pattern rules and PIR (Public Insurance Registry) rollout. Management tone is compliance-ready but cautious on timing and impact. Market share opacity: The switch to 1/n basis reporting starting Q2 makes fresh/renewal/portability splits non-comparable to prior years. The company's claim of ~40% market share on new-to-insurance is an estimate, not a filed number. Clarity only returns in FY28.